

(43) International Publication Date
7 October 2010 (07.10.2010)(10) International Publication Number
WO 2010/115055 A1

(51) International Patent Classification:

A61K 31/198 (2006.01) A61K 31/192 (2006.01)
A61P 1/16 (2006.01) C07C 57/46 (2006.01)
C07C 229/26 (2006.01)

(21) International Application Number:

PCT/US2010/029708

(22) International Filing Date:

1 April 2010 (01.04.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/166,676 3 April 2009 (03.04.2009) US

(71) Applicant (for all designated States except US): **OCERA THERAPEUTICS, INC.** [US/US]; 12651 High Bluff Drive, Suite 230, San Diego, CA 92130 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANDERSON, Keith** [CA/US]; 15022 Cross Stone Drive, San Diego, CA 92127 (US). **BEHLING, Jim** [US/US]; 3936 State Route 17 North, Eagle River, WI 54521 (US). **DOUGAN, Christine, Henderson** [GB/US]; 69 Turnberry Gardens, Westerwood, Cumbernauld, Scotland, Glasgow G68 0AY (GB). **WATT, Stephen, William** [GB/GB]; 1 Lawson Way, Tranent, Scotland, East Lothian EH33 0QU (GB). **MANINI, Peter** [CH/CH]; Via Dr. Falleroni 2, CH-6512

Giubiasco (CH). **FIGINI, Attilia** [CH/CH]; Via Francesco Chiesa 65a, CH-6850 Mendrisio (CH).

(74) Agent: **HART, Daniel**; Knobbe Martens Olson & Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, CA 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

[Continued on next page]

(54) Title: L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF




FIG. 1

X-ray powder diffraction pattern of Form I

(57) Abstract: Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.



Published:

— *with international search report (Art. 21(3))*